Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clear-cell and papillary serous cancer: treatment options
Autore:
Trope, C; Kristensen, GB; Abeler, VM;
Indirizzi:
Norwegian Radium Hosp, Univ Clin, Dept Gynecol Oncol, N-0310 Oslo, Norway Norwegian Radium Hosp Oslo Norway N-0310 ecol Oncol, N-0310 Oslo, Norway Norwegian Radium Hosp, Univ Clin, Dept Pathol, N-0310 Oslo, Norway Norwegian Radium Hosp Oslo Norway N-0310 ept Pathol, N-0310 Oslo, Norway
Titolo Testata:
BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY
fascicolo: 3, volume: 15, anno: 2001,
pagine: 433 - 446
SICI:
1521-6934(200106)15:3<433:CAPSCT>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
LONG-TERM SURVIVAL; ENDOMETRIAL CANCER; CARCINOMA UPSC; PATHOLOGIC FINDINGS; NUCLEAR GRADE; DNA-PLOIDY; ADENOCARCINOMA; P53; DOXORUBICIN; EXPRESSION;
Keywords:
endometrioid carcinoma; carcinoma; uterine papillary serous carcinoma (UPSC); clear-cell adenocarcinoma (CCC); prognosis; nuclear grade; flow cytometry; DNA ploidy; p53 immunohistochemistry; surgery; chemotherapy; pelvic; abdominal irradiation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
59
Recensione:
Indirizzi per estratti:
Indirizzo: Trope, C Norwegian Radium Hosp, Univ Clin, Dept Gynecol Oncol, N-0310 Oslo, Norway Norwegian Radium Hosp Oslo Norway N-0310 l, N-0310 Oslo, Norway
Citazione:
C. Trope et al., "Clear-cell and papillary serous cancer: treatment options", BEST P R CL, 15(3), 2001, pp. 433-446

Abstract

Clear-cell carcinoma (CCC) and serous papillary carcinoma of the endometrium (UPSC) are rare subtypes of endometrial carcinoma (10%). The histological diagnosis can be made on the dilation and curettage specimens in both types in a very high percentage of the cases. This is important in the planning of treatment. CCC and UPSC are associated with about 50% of all relapses occurring in endometrial carcinoma, and the 5-year survival rate is, on average, 42% and 27% respectively. Surgico-pathological stage, age, and vesselinvasion are independent prognostic factors for both groups. The recurrence rate is extremely high, and the most frequent extra-pelvic sites of relapse are the upper abdomen, lungs and liver. Stage la patients treated with complete surgical staging alone have a low risk of relapse and need not be offered adjuvant systemic therapy or pelvic radiation. The treatment of patients with CCC and UPSC stage Ib, Ic, II and III should include radical debulking surgery and some form of adjuvant therapy, but it is nor, clear whichtype is most effective. Adjuvant pelvic radiotherapy plus intracavitary radiotherapy is usually given in early-stage disease and pelvic radio therapy/or whole abdomen irradiation plus adjuvant systemic chemotherapy (PAC) in advanced disease. However, we are urgently waiting for a large prospective randomized study to compare both modalities. Paclitaxel, alone or in combination, is currently being tested in phase II studies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/06/20 alle ore 15:12:01